RTP Mobile Logo
Select Publications

Erika Hamilton

Devanaboyina M et al. A retrospective study of characteristics and survival in patients with breast cancer brain metastases classified by subtype using NCI SEER registry. ASCO 2021;Abstract 1031.

Jerusalem GHM et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial. ASCO 2021;Abstract 526.

Saura C et al. Impact of neratinib on outcomes in HER2-positive metastatic breast cancer patients with central nervous system disease at baseline: Findings from the phase 3 NALA trial. San Antonio Breast Cancer Symposium 2020;Abstract PD13-09.

Stringer-Reasor EM et al. Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. ASCO 2021;Abstract 1044.

Yan M et al. Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study. ASCO 2021;Abstract 1037.

Ian Krop

Chan A et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer 2021;21(1):80-91.e7. Abstract

Geyer CE et al. Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05). San Antonio Breast Cancer Symposium 2020;Abstract OT-03-01.

Harbeck N et al. De-escalated neoadjuvant pertuzumab + trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results. ASCO 2021;Abstract 503.

Waks AG et al. The DAPHNE trial: A feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-HP (THP) in HER2-positive breast cancer. San Antonio Breast Cancer Symposium 2020;Abstract PD3-05.

Joyce O’Shaughnessy

Goutsouliak K et al. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol 2020;17(4):233-50. Abstract

Lin NU et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol 2020;38(23):2610-9. Abstract

Modi S et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020;382(7):610-21. Abstract

Saura C et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial. J Clin Oncol 2020;38:3138-49.Abstract

Tarantino P et al. HER2-low breast cancer: Pathological and clinical landscape. J Clin Oncol 2020;38(17):1951-62. Abstract

PR Newswire. Byondis announces positive topline results of pivotal phase III TULIP® study in patients with HER2-positive unresectable locally advanced or metastatic breast cancer [press release]. June 8. 2021.  https://www.prnewswire.com/news-releases/byondis-announces-positive-topline-results-of-pivotal-phase-iii-tulip-study-in-patients-with-her2-positive-unresectable-locally-advanced-or-metastatic-breast-cancer-301306890.html

Businesswire. DESTINY-Breast09 head-to-head first-line phase 3 trial of ENHERTU® initiated in patients with HER2 positive metastatic breast cancer [press release]. June 14, 2021. https://www.businesswire.com/news/home/20210614005114/en/DESTINY-Breast09-Head-to-Head-First-Line-Phase-3-Trial-of-ENHERTU%C2%AE-Initiated-in-Patients-with-HER2-Positive-Metastatic-Breast-Cancer